Astex
  • Discover Astex
    • Our Mission & Values
    • Our Leadership Team
      • Harren Jhoti
      • David Rees
      • John Lyons
      • Chris Murray
      • Jeremy Carmichael
      • Lee Dawson
      • Tom Heightman
      • Neil Jones
      • Nicola Wallis
      • Mohammad Azab
      • Martin Buckland
      • Harold N. Keer
      • Nipun Davar
      • Yong Hao
      • Joseph Iovino
      • Samuel Jason
      • Charles LaPree
      • Shinichi Sato
      • Nancy Worrell
    • Our History
    • Corporate Social Responsibility
  • R&D
    • Clinical Pipeline
      • Guadecitabine (SGI-110) DNMT inhibitor (Treatment Naïve AML)
      • Guadecitabine (SGI-110) DNMT inhibitor (Relapsed/Refractory AML)
      • Guadecitabine (SGI-110) DNMT inhibitor (Relapsed/Refractory MDS or CMML)
      • Guadecitabine (SGI-110) DNMT inhibitor (Solid Tumors)
      • ASTX029 Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
      • ASTX727 Oral DNMT inhibitor (Hematologic Malignancies)
      • ASTX660 Dual IAP Antagonist (Solid Tumors & Lymphomas)
      • Kisqali®(ribociclib) CDK4/6 inhibitor (Oncology)
      • AZD3293 (lanabecestat) Beta Secretase (BACE) inhibitor (Alzheimer’s disease)
      • AZD5363 PKB/Akt Inhibitor (Oncology)
      • JNJ42756493 (erdafitinib) FGFr inhibitor (Oncology)
      • Multiple Targets and Therapeutic Areas
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation
  • Partnering
  • Our People
    • Career Opportunities
  • Media
    • Press Releases
      • Press Releases – Archive
    • Conferences & Meetings
    • Presentations & Publications
    • Astex in the News
  • Contact
  • Search
  • Menu
You are here: Home / 2010 / SuperGen Reports 2010 Second Quarter Financial Results

SuperGen Reports 2010 Second Quarter Financial Results

2 August 2010/in 2010, News /by webadmin

SuperGen Reports 2010 Second Quarter Financial Results

/wp-content/uploads/2016/11/logo.png 0 0 webadmin /wp-content/uploads/2016/11/logo.png webadmin2010-08-02 12:23:202016-11-28 12:23:44SuperGen Reports 2010 Second Quarter Financial Results

Copyright © Astex Pharmaceuticals
All rights reserved

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal

Member of the Otsuka Group

Astex scientists describe novel HSP90 inhibitors in two key publications in... Astex and Multiple Myeloma Research Consortium (MMRC) Announce Start of Phase...
Scroll to top
By continuing to use this website you will be agreeing to our Terms & Conditions, our Privacy Policy, and the use of cookies.continue